Cumberland Pharmaceuticals

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)	idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder	Recruiting	Phase 2	2026-09-02	NCT05571059
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension	Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, limited cutaneous systemic sclerosis, skin disorder, systemic sclerosis	Active, not recruiting	Phase 2	2026-09-02	NCT02682511
Imaging Acetadote Metabolism in Glioblastoma	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor	Recruiting	Early phase 1	2026-06-23	NCT07387666
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage	Hemorrhage, Intracranial Hemorrhages, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subarachnoid Hemorrhage, Aneurysmal, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, subarachnoid hemorrhage, vascular disorder	Recruiting	Phase 4	2025-12-26	NCT06119061

Clinical trials